Multivariable analysis showed that IPM-HR, older age, TP53 mutation, FLT3-ITD, and DNMT3A mutations were all independent adverse prognostic factors for OS in AML patients with intermediate and adverse-cytogenetic risk (Table 1). Here, DNMT3A is linked to acute myeloid leukemia.